You are here

ESMO

Gilead scores US approval for breast cancer drug that wowed ESMO

Gilead scores US approval for breast cancer drug that wowed ESMO

Pharmaforum

Gilead Sciences

triple negative breast cancer

Flag link:

Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program

Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program

Endpoints

Autolus Therapeutics

diffuse large B-cell lymphoma

Flag link:

Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst

Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst

Fierce Pharma

Gilead Sciences

Flag link:

Esmo 2020 – can Alkermes succeed where Nektar failed?

Esmo 2020 – can Alkermes succeed where Nektar failed?

EP Vantage

Flag link:

AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial

AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial

BioSpace

clinical trials

non-small cell lung cancer

Flag link:

Esmo 2020 – More encouraging signs for checkpoint bispecifics

Esmo 2020 – More encouraging signs for checkpoint bispecifics

EP Vantage

Flag link:

Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients

Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients

BioSpace

Mirati Therapeutics

urothelial cancer

Flag link:

#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap

#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap

Endpoints

Bristol-Myers Squibb

esophageal cancer

Flag link:

ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats

ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats

Fierce Pharma

non-small cell lung cancer

Flag link:

Amgen publishes, presents data on therapy with ‘undruggable’ target

Amgen publishes, presents data on therapy with ‘undruggable’ target

MedCity News

non-small cell lung cancer

Flag link:

Esmo 2020 – some backing for Beigene’s unusual combo approach

Esmo 2020 – some backing for Beigene’s unusual combo approach

EP Vantage

urothelial cancer

Flag link:

ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga

ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga

Fierce Biotech

prostate cancer

Flag link:

ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More

ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More

BioSpace

clinical tirals

Flag link:

ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question

ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question

Fierce Pharma

triple negative breast cancer

Flag link:

ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer

ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer

Fierce Pharma

Flag link:

ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial

ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial

Fierce Pharma

head and neck cancer

clinical trials

Flag link:

ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray

ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray

Fierce Pharma

Flag link:

ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer

ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer

Fierce Pharma

metastatic bladder cancer

Flag link:

#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?

#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?

Endpoints

non-small cell lung cancer

Flag link:

Seattle Genetics stays step ahead of rivals with bladder cancer data

Seattle Genetics stays step ahead of rivals with bladder cancer data

BioPharma Dive

Seattle Genetics

clinical trials

Flag link:

Pages